Celera Diagnostics to Market Gene-Based HIV Test
December 12, 2002
Celera Diagnostics, an Alameda, Calif., venture supported by Celera Genomics and Applied Biosystems Group, said it received clearance from the U.S. Food and Drug Administration to market a gene-based HIV test. The test is designed to detect mutations in HIV that create resistance to certain drug treatments. Studies have found that up to 78 percent of patients show resistance to drugs used to treat HIV. Genetic testing is common for HIV patients, but Celera Genomics Chief Executive Kathy Ordoñez said Celera Diagnostics' test could help standardize the process. A unit of Abbott Laboratories will distribute the system.
This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. Visit the CDC's website to find out more about their activities, publications and services.